Departmet of Visceral Surgery, National Institute of Oncology, Budapest, Hungary.
Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary.
Pathol Oncol Res. 2022 Apr 27;28:1610315. doi: 10.3389/pore.2022.1610315. eCollection 2022.
The literature data regarding colon cancer patients with liver-only metastases (CLM) show that NLR determined before metastasectomy is a prognostic marker of shorter relapse-free survival (RFS), but no results has been reported to date for rectal cancer patients with liver-only metastases (RLM). This study aimed to investigate the NLR and SII in CLM and RLM. Relapse-free (RFS) and overall survival (OS) were evaluated in 67 CLM and 103 RLM patients with a median follow-up of 46.5 and 59.8 months, respectively. Pre- and/or postoperative chemotherapy ± targeted treatment was applied in 96% and 87% of CLM and RLM patients, respectively. The cut-off level for hematologic parameters were determined by receiver operating characteristic (ROC) analysis. Univariate analysis was performed by Kaplan-Meier method and log rank test. For multivariate analysis Cox regression was applied. In univariate analysis low NLR (cut-off 2) and SII (535) were predictors of longer RFS in case of CLM ( < 0.01). In contrast, for RLM high NLR (2.42) and SII (792) were predictors of longer RFS ( < 0.001). For RLM both NLR and SII proved to be independent markers of RFS (HR 0.66 (95% CI 0.52-0.84) and 0.73 (0.57-0.91), respectively) and OS (0.76 (0.58-0.99) and 0.66 (0.5-0.87), respectively). Only NLR (1.44 (1.04-1.99)) was independent marker of RFS for CLM. The preoperative treatment has not influenced the role of NLR or SII. In contrast to CLM, in RLM the high NLR or SII determined before metastasectomy proved to be independent prognostic factors of longer RFS and OS.
文献资料显示,对于仅有肝转移的结肠癌(CLM)患者,转移前的中性粒细胞与淋巴细胞比值(NLR)是无复发生存期(RFS)较短的预后标志物,但迄今为止,尚无关于仅有肝转移的直肠癌(RLM)患者的相关结果报道。本研究旨在探讨 NLR 和 SII 在 CLM 和 RLM 中的作用。对 67 例 CLM 和 103 例 RLM 患者进行了中位随访时间分别为 46.5 个月和 59.8 个月的无复发生存(RFS)和总生存(OS)评估。96%和 87%的 CLM 和 RLM 患者分别接受了术前和/或术后化疗+靶向治疗。通过接收者操作特征(ROC)分析确定了血液学参数的截断值。单因素分析采用 Kaplan-Meier 法和对数秩检验。对于多因素分析,采用 Cox 回归分析。在单因素分析中,CLM 患者 NLR (截断值 2)和 SII (535)较低提示 RFS 较长(<0.01)。相反,对于 RLM,高 NLR(2.42)和 SII(792)提示 RFS 较长(<0.001)。对于 RLM,NLR 和 SII 均被证明是 RFS 的独立标志物(HR 分别为 0.66(95%CI 0.52-0.84)和 0.73(0.57-0.91))和 OS(0.76(0.58-0.99)和 0.66(0.5-0.87))。仅 NLR(1.44(1.04-1.99))是 CLM 患者 RFS 的独立标志物。术前治疗并未影响 NLR 或 SII 的作用。与 CLM 相反,在 RLM 中,转移前确定的高 NLR 或 SII 被证明是 RFS 和 OS 较长的独立预后因素。